FDA Approves Vimseltinib for Symptomatic Tenosynovial Giant Cell Tumour By Ogkologos - April 4, 2025 654 0 Facebook Twitter Google+ Pinterest WhatsApp Evidence for efficacy is based on the results from the MOTION study Source RELATED ARTICLESMORE FROM AUTHOR FX-909 Demonstrates Acceptable Safety and Preliminary Antitumour Activity, Establishing a Proof of Concept for PPARγ Inverse Agonism in Advanced Urothelial Cancer Pimicotinib Shows Robust Antitumour Activity and Clinically Meaningful Improvements in Patients with Tenosynovial Giant Cell Tumour FDA Grants Accelerated Approval to Zongertinib for Unresectable or Metastatic Non-Squamous NSCLC MOST POPULAR Withdrawal of the Application to Change the EMA Marketing Authorisation for... December 2, 2022 5-Yr-Old Cancer Survivor Used His Birthday To Collect Toys For Sick... October 15, 2019 How to Strengthen Your Immune System: Part 1 September 17, 2020 Cancer Rehabilitation Starts at Diagnosis July 6, 2021 Load more HOT NEWS FX-909 Demonstrates Acceptable Safety and Preliminary Antitumour Activity, Establishing a Proof... Re-Thinking Community ESMO Targeted Anticancer Therapies Congress 2021, 1-2 March Marine Runs Five Marathons in Five Days to Help Fund Sister’s...
